

Johan Gobom

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/571258/publications.pdf>

Version: 2024-02-01

63
papers

2,273
citations

257450

24
h-index

223800

46
g-index

68
all docs

68
docs citations

68
times ranked

3033
citing authors

#	ARTICLE	IF	CITATIONS
1	Sample purification and preparation technique based on nano-scale reversed-phase columns for the sensitive analysis of complex peptide mixtures by matrix-assisted laser desorption/ionization mass spectrometry. <i>Journal of Mass Spectrometry</i> , 1999, 34, 105-116.	1.6	679
2	Mass Spectrometry-Based Candidate Reference Measurement Procedure for Quantification of Amyloid- β in Cerebrospinal Fluid. <i>Clinical Chemistry</i> , 2014, 60, 987-994.	3.2	132
3	Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2019, 137, 279-296.	7.7	128
4	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. <i>Brain</i> , 2020, 143, 3776-3792.	7.6	89
5	Detection and Quantification of Neurotensin in Human Brain Tissue by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry. <i>Analytical Chemistry</i> , 2000, 72, 3320-3326.	6.5	84
6	An Integrated Workflow for Multiplex CSF Proteomics and Peptidomics Identification of Candidate Cerebrospinal Fluid Biomarkers of Alzheimer's Disease. <i>Journal of Proteome Research</i> , 2015, 14, 654-663.	3.7	84
7	Reference measurement procedure for CSF amyloid beta ($A\beta$) ₁₋₄₂ and the CSF $A\beta$ ₁₋₄₂ / $A\beta$ ₁₋₄₀ ratio – a cross-validation study against amyloid PET. <i>Journal of Neurochemistry</i> , 2016, 139, 651-658.		78
8	The amyloid- β degradation pattern in plasma – A possible tool for clinical trials in Alzheimer's disease. <i>Neuroscience Letters</i> , 2014, 573, 7-12.	2.1	62
9	Peptidome Analysis of Cerebrospinal Fluid by LC-MALDI MS. <i>PLoS ONE</i> , 2012, 7, e42555.	2.5	57
10	Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5-90 years. <i>Brain Communications</i> , 2022, 4, .	3.3	57
11	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. <i>Journal of Internal Medicine</i> , 2021, 290, 583-601.	6.0	54
12	Targeted proteomics in Alzheimer's disease: focus on amyloid- β . <i>Expert Review of Proteomics</i> , 2008, 5, 225-237.	3.0	49
13	Genome-scale metabolic network reconstruction of model animals as a platform for translational research. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	48
14	Round robin test on quantification of amyloid- β ₁₋₄₂ in cerebrospinal fluid by mass spectrometry. <i>Alzheimer's and Dementia</i> , 2016, 12, 55-59.	0.8	46
15	A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 13333.	3.3	45
16	Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 303-313.	2.6	44
17	Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 207-219.	2.3	44
18	First amyloid β ₁₋₄₂ certified reference material for recalibrating commercial immunoassays. <i>Alzheimer's and Dementia</i> , 2020, 16, 1493-1503.	0.8	42

#	ARTICLE	IF	CITATIONS
19	Explorative and targeted neuroproteomics in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2015, 1854, 769-778.	2.3	41
20	Levels of ADAM10 are reduced in Alzheimer's disease CSF. <i>Journal of Neuroinflammation</i> , 2018, 15, 213.	7.2	39
21	Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12179.	2.4	35
22	Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. <i>Parkinsonism and Related Disorders</i> , 2017, 37, 65-71.	2.2	34
23	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2022, 17, 27.	10.8	30
24	Expanding the cerebrospinal fluid endopeptidome. <i>Proteomics</i> , 2017, 17, 1600384.	2.2	28
25	APOE ϵ 4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 65.	6.2	28
26	Arginine vasopressin in the cytoplasm and nuclear fraction of lymphocytes from healthy donors and patients with depression or schizophrenia. <i>Peptides</i> , 2001, 22, 67-72.	2.4	23
27	Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer's disease: an update. <i>Expert Review of Proteomics</i> , 2017, 14, 1007-1020.	3.0	21
28	Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β 2 clearance pathway. <i>Molecular Neurodegeneration</i> , 2017, 12, 18.	10.8	17
29	Neuroigin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers. <i>Acta Neuropathologica Communications</i> , 2021, 9, 19.	5.2	17
30	A single dose of the β -secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 11.	6.2	15
31	Fluid-based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases. <i>Journal of Neurochemistry</i> , 2019, 151, 417-434.	3.9	15
32	Method for Qualitative Comparisons of Protein Mixtures Based on Enzyme-Catalyzed Stable-Isotope Incorporation. <i>Journal of Proteome Research</i> , 2005, 4, 2109-2116.	3.7	14
33	Protein aggregate formation permits millennium-old brain preservation. <i>Journal of the Royal Society Interface</i> , 2020, 17, 20190775.	3.4	11
34	Optimized sample preparation and data analysis for TMT proteomic analysis of cerebrospinal fluid applied to the identification of Alzheimer's disease biomarkers. <i>Clinical Proteomics</i> , 2022, 19, 13.	2.1	10
35	Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease. <i>Clinical Mass Spectrometry</i> , 2019, 14, 74-82.	1.9	9
36	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. <i>Proteomes</i> , 2021, 9, 36.	3.5	9

#	ARTICLE	IF	CITATIONS
37	Increased CSF-decorin predicts brain pathological changes driven by Alzheimer's A β amyloidosis. Acta Neuropathologica Communications, 2022, 10, .	5.2	8
38	The influence of the R47H triggering receptor expressed on myeloid cells 2 variant on microglial exosome profiles. Brain Communications, 2021, 3, fcab009.	3.3	7
39	Peptidomic analysis of cartilage and subchondral bone in OA patients. European Journal of Clinical Investigation, 2019, 49, e13082.	3.4	6
40	Differential Stimulation of Pluripotent Stem Cell-Derived Human Microglia Leads to Exosomal Proteomic Changes Affecting Neurons. Cells, 2021, 10, 2866.	4.1	6
41	Advancing cerebrospinal fluid biomarker discovery by mass spectrometry. Neurodegenerative Disease Management, 2015, 5, 371-373.	2.2	4
42	A mass spectrometric approach to study the interaction of amyloid β peptides with human α -2-macroglobulin. Biochimie, 2021, 191, 62-68.	2.6	4
43	Sample purification and preparation technique based on nano-scale reversed-phase columns for the sensitive analysis of complex peptide mixtures by matrix-assisted laser desorption/ionization mass spectrometry. Journal of Mass Spectrometry, 1999, 34, 105.	1.6	4
44	Effects of age, amyloid, sex, and <i>APOE</i> ϵ 4 on the CSF proteome in normal cognition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12286.	2.4	4
45	Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2023, 19, 807-820.	0.8	4
46	Sample Preparation for Endopeptidomic Analysis in Human Cerebrospinal Fluid. Journal of Visualized Experiments, 2017, , .	0.3	1
47	CSF proteomic profiling of mild cognitive impairment individuals with suspected non-Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2020, 16, e047247.	0.8	1
48	A novel antibody-free mass spectrometry panel of CSF biomarkers for synaptic dysfunction. Alzheimer's and Dementia, 2021, 17, .	0.8	1
49	[P3 ϵ 084]: N-TERMINAL FRAGMENT OF TAU: ASSAY DEVELOPMENT WITH IN-HOUSE CLEAVAGE-SPECIFIC ANTIBODY. Alzheimer's and Dementia, 2017, 13, P964.	0.8	0
50	[P2 ϵ 246]: NOVEL CSF FRAGMENTS OF TAU: CANDIDATE BIOMARKERS OF ALZHEIMER'S DISEASE AND TAUOPATHIES. Alzheimer's and Dementia, 2017, 13, P706.	0.8	0
51	[P4 ϵ 382]: PROTEOMIC CHANGES IN ZEBRAFISH LACKING THE AMYLOID PRECURSOR HOMOLOG, APPB, USING A HIGH-THROUGHPUT DIFFERENTIAL PROTEOMIC APPROACH. Alzheimer's and Dementia, 2017, 13, P1439.	0.8	0
52	[P3 ϵ 075]: PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS. Alzheimer's and Dementia, 2017, 13, P960.	0.8	0
53	O3 ϵ 14 ϵ 04: THE PROTEIN-TO-PEPTIDE RATIO IMPROVES THE PERFORMANCE OF MICROTUBULE-ASSOCIATED PROTEIN TAU IN CSF AS AN ALZHEIMER BIOMARKER. Alzheimer's and Dementia, 2018, 14, P1060.	0.8	0
54	P4 ϵ 525: ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1515.	0.8	0

#	ARTICLE	IF	CITATIONS
55	A novel proteomics assay allows parallel quantitation of a panel of synaptic proteins in human cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , 2020, 16, e042578.	0.8	0
56	Synaptic proteins relate to memory scores in preclinical Alzheimer's disease and cognitively healthy controls depending on amyloid. <i>Alzheimer's and Dementia</i> , 2020, 16, e046102.	0.8	0
57	Ultra-performance liquid chromatography-tandem mass spectrometry method for analysis of tau in human cerebrospinal fluid without the need of immunocapture. <i>Alzheimer's and Dementia</i> , 2020, 16, e040373.	0.8	0
58	Author reply to the Letter to the Editor by Prof. Dr. Dr Mischak: "Re-analysis of peptidomic analysis of cartilage and subchondral bone in OA patients". <i>European Journal of Clinical Investigation</i> , 2020, 50, e13260.	3.4	0
59	Decorin is an early CSF biomarker of Alzheimer's A β 2 amyloidosis. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
60	Alzheimer's disease genetic risk variants show brain cell type-specific associations with protein levels in cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , 2021, 17, e049531.	0.8	0
61	Mass spectrometric measurement of six site-specific tau phosphorylations in CSF and blood of Alzheimer's disease patients. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
62	Cerebrospinal fluid proteomic profiling of individuals with prodromal Alzheimer's disease classified using two different neurodegenerative biomarkers (N) in A/T/N classification. <i>Alzheimer's and Dementia</i> , 2021, 17, e053030.	0.8	0
63	Immune protein levels in cerebrospinal fluid: Associations with memory scores across the AD spectrum.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e055451.	0.8	0